10-Q: Integer Holdings Reports Strong Sales Growth Amidst Strategic Acquisitions and Debt Restructuring

Integer Holdings Corporation reported increased sales and gross profit for the second quarter and first six months of 2025, driven by strategic acquisitions and new product ramps, despite a significant one-time debt conversion expense impacting net income for the six-month period.

Summary

• Sales for the second quarter of 2025 increased by $48.6 million (11.4%) to $476.5 million, and for the first six months of 2025, sales increased by $78.2 million (9.4%) to $913.9 million, compared to the same periods in 2024.
• Cardio & Vascular (C&V) sales grew by 24.0% in Q2 2025 and 20.4% in the first six months of 2025, driven by new product ramps, acquisitions, and strong neurovascular demand.
• Cardiac Rhythm Management & Neuromodulation (CRM&N) sales increased by 2.3% in both Q2 and the first six months of 2025, due to growth in emerging neuromodulation customers and normalized cardiac rhythm management.
• Other Markets sales decreased by 37.9% in Q2 2025 and 37.6% in the first six months of 2025, primarily due to the planned Portable Medical Exit.
• Gross profit increased by $11.8 million (10.0%) in Q2 2025 and $23.8 million (10.6%) in the first six months of 2025, benefiting from higher sales volume leverage, supply chain efficiencies, and recent acquisitions.
• Operating income rose by 8.9% in Q2 2025 to $59.3 million and by 16.8% in the first six months of 2025 to $108.9 million.
• Interest expense decreased by 33.1% in Q2 2025 to $9.8 million and by 14.0% in the first six months of 2025 to $24.6 million, primarily due to lower interest rates on outstanding borrowings and a favorable shift to fixed-rate debt.
• A significant debt conversion inducement expense of $46.7 million was recognized in the first quarter of 2025, related to the partial exchange of 2028 Convertible Notes.
• Net income from continuing operations for the first six months of 2025 was $14.5 million, a 71.9% decrease from $51.8 million in the same period of 2024, largely due to the debt conversion expense.
• Diluted earnings per share from continuing operations for the first six months of 2025 was $0.41, down 72.1% from $1.47 in the prior year period.
• The effective tax rate for the first six months of 2025 was 55.4%, significantly higher than 20.2% in 2024, mainly due to the non-deductible induced conversion expense.
• Acquired Precision Coating LLC on January 7, 2025, for $153.5 million and VSi Parylene on February 28, 2025, for $24.0 million, expanding service offerings and coating capabilities.
• Issued $1.0 billion in 1.875% Convertible Senior Notes due 2030 on March 18, 2025, using proceeds to fund capped calls, exchange a portion of 2028 Convertible Notes, and pay down existing debt.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While the company demonstrated strong operational performance with significant sales growth and improved gross profit, particularly in key product lines, the overall financial results for the six-month period were heavily impacted by a large, one-time debt conversion expense. The strategic acquisitions and debt restructuring are positive long-term moves, but the immediate financial optics are skewed by the non-recurring charge.

Positives

• Sales increased by 11.4% in Q2 2025 and 9.4% in the first six months of 2025, demonstrating strong top-line growth.
• Cardio & Vascular (C&V) sales showed robust growth of 24.0% in Q2 2025 and 20.4% in the first six months of 2025, driven by new product ramps and strong customer demand.
• Gross profit increased by 10.0% in Q2 2025 and 10.6% in the first six months of 2025, indicating improved operational efficiency and leverage from higher sales volume.
• Operating income increased by 8.9% in Q2 2025 and 16.8% in the first six months of 2025, reflecting effective cost management relative to sales growth.
• Interest expense decreased by 33.1% in Q2 2025 and 14.0% in the first six months of 2025, due to lower interest rates and a strategic shift to 91% fixed-rate debt.
• Successful acquisitions of Precision Coating LLC and VSi Parylene enhance service offerings and proprietary coating capabilities, aligning with the company's tuck-in acquisition strategy.
• The company maintains strong liquidity with $784.7 million of available borrowing capacity under its Revolving Credit Facility as of June 27, 2025.
• The Total Net Leverage Ratio of approximately 2.7:1.0 and Interest Coverage Ratio of approximately 10.4:1.0 indicate healthy financial covenant compliance.

Negatives

• Net income from continuing operations for the first six months of 2025 significantly decreased by 71.9% to $14.5 million, primarily due to a $46.7 million debt conversion inducement expense.
• Diluted earnings per share from continuing operations for the first six months of 2025 fell by 72.1% to $0.41, impacted by the one-time debt conversion expense.
• The effective tax rate for the first six months of 2025 increased substantially to 55.4% from 20.2% in 2024, largely due to the non-deductible induced conversion expense.
• Other Markets sales decreased significantly by 37.9% in Q2 2025 and 37.6% in the first six months of 2025, attributed to the Portable Medical Exit.
• Cash and cash equivalents decreased by $23.4 million from December 31, 2024, to $23.1 million as of June 27, 2025, primarily due to cash used in investing activities for acquisitions and debt payments.

Risks

• Dependence upon a limited number of customers and pricing pressures from contractual restraints.
• Reliance on third-party suppliers for raw materials, key products, and subcomponents.
• Potential for interruptions in manufacturing operations.
• Uncertainty surrounding macroeconomic and geopolitical factors, including supply chain disruptions, inflationary pressure, elevated interest rates, and conflicts in the Middle East.
• Ability to attract, train, and retain a sufficient number of qualified associates.
• Potential for harm to reputation and competitive advantage due to quality problems related to products.
• Dependence upon information technology systems and the ability to prevent cyber-attacks.
• Impact of global climate change and emphasis on Environmental, Social, and Governance (ESG) matters.
• Dependence upon senior management team and key technical personnel.
• Intense competition and the ability to successfully market products and respond to changes in technology.
• Ability to successfully identify, make, and integrate acquisitions.
• Fluctuations in operating results making accurate future performance forecasts challenging.
• Significant amount of outstanding indebtedness and the ability to remain in compliance with financial covenants.
• Economic and credit market uncertainties that could interrupt access to capital markets.
• Conditional conversion feature of the 2028 Convertible Notes and 2030 Convertible Notes potentially impacting liquidity and diluting ownership interests.
• Counterparty risk associated with capped call transactions.
• Financial and market risks related to international sales and operations, including foreign currency fluctuations.
• Complex international tax profile and the ability to realize the full value of intangible assets.
• Regulatory issues from product complaints, recalls, or audits.
• Potential for product liability or intellectual property claims and the ability to protect intellectual property.
• Ability to comply with customer-driven policies and third-party standards or certification requirements.
• Ability and cost to comply with environmental regulations.
• Healthcare industry being highly regulated and subject to cost containment measures that could reduce sales.

Future Outlook

The company expects Portable Medical sales to wind down with the final market exit occurring in 2025. It is currently evaluating the potential impact of the One Big Beautiful Bill Act (OBBBA) on its condensed consolidated financial statements, but does not anticipate a material impact. The 2025 provision for income taxes includes the impact of the Pillar Two 15% Global Minimum Tax, and the company continues to evaluate the potential impact of the Pillar Two Framework on future periods. The company believes its projected cash flows from operations, available cash, and Revolving Credit Facility borrowings are sufficient to meet working capital, debt service, and capital expenditure requirements for the next twelve months.

Management Comments

• "I want to offer my sincere thanks for your continued partnership and outstanding leadership. Together we will achieve the results that will make the difference in Integer's long-term success." Joe Dziedzic, President & Chief Executive Officer (in letter to John Harris regarding special LTI award).
• "We selectively evaluate acquisitions as a means to acquire additional technology or manufacturing capabilities to expand our product offering in our key existing growth markets."
• "Consistent with our tuck-in acquisition strategy, the acquisitions of Precision and VSi further increase our service offerings to include differentiated and proprietary coatings capabilities that position us to better meet customers evolving needs."
• "We monitor economic conditions closely. In response to reductions in revenue, we can take actions to align our cost structure with changes in demand and manage our working capital."

Industry Context

Integer Holdings Corporation, a leading medical device contract development and manufacturing organization, is strategically expanding its capabilities through targeted acquisitions like Precision Coating LLC and VSi Parylene. These acquisitions enhance its service offerings in high-value surface coating and parylene solutions, aligning with broader industry trends towards specialized, integrated manufacturing services for complex medical devices. The strong growth in Cardio & Vascular and emerging Neuromodulation markets reflects robust demand in these critical healthcare sectors, while the planned exit from the Portable Medical market indicates a strategic focus on higher-growth, more profitable segments. The company's debt restructuring, including the issuance of convertible notes, is a common financial strategy in the industry to optimize capital structure and fund growth initiatives.

Comparison to Industry Standards

• The filing does not provide specific comparable company data or global benchmarks to assess the results against industry standards. Therefore, a direct comparison to specific comparable companies, projects, or results is not possible based solely on the provided information.

Management Changes

Legal Proceedings

• No new material legal proceedings were reported in the quarter ended June 27, 2025, and no material developments occurred in previously disclosed legal proceedings.

Stakeholder Impact

• Shareholders: Potential dilution from convertible notes, but also benefit from strategic acquisitions and debt restructuring aimed at long-term growth. Executive stock ownership guidelines align management interests with shareholders.
• Employees: Management changes, including retirements and retention awards, indicate a focus on smooth transitions and talent retention. Acquisitions may lead to integration efforts and potential organizational changes.
• Customers: Expanded service offerings and differentiated coating capabilities from recent acquisitions are expected to better meet evolving customer needs and accelerate time to market for customer products.
• Creditors: Debt restructuring, including the issuance of 2030 Convertible Notes and partial exchange of 2028 Convertible Notes, impacts the company's debt profile and interest expense, with a significant portion of debt now fixed-rate.

Next Steps

• Complete the Portable Medical Exit with final sales and market exit occurring in 2025.
• Continue to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on condensed consolidated financial statements.
• Continue to evaluate the potential impact of the OECD Pillar Two Framework on future periods.
• Joseph W. Dziedzic will transition from CEO to Special Advisor to the Company, supporting the CEO succession, until his retirement on March 31, 2026.
• John Harris will continue employment until his retirement on March 31, 2027, and will train a successor for his role.

Key Dates

Recommendation

The company demonstrates strong operational performance with robust sales growth in key medical device segments and strategic acquisitions that enhance its capabilities. This indicates a healthy underlying business. However, the significant one-time debt conversion expense heavily impacted net income and EPS for the six-month period, obscuring the operational strengths. While the debt restructuring improves the long-term capital structure by fixing a larger portion of debt, the immediate financial results are mixed. Given the strong operational momentum balanced by the non-recurring financial charge and ongoing integration efforts, a 'hold' recommendation is appropriate for a seasoned investor, awaiting further clarity on the sustained impact of the strategic initiatives and the full realization of acquisition benefits.

Keywords

Medical Device, Contract Manufacturing, Cardio & Vascular, Neuromodulation, Cardiac Rhythm Management, SEC Filing, Quarterly Report, Acquisitions, Convertible Notes, Debt Restructuring, Financial Performance, Supply Chain, Executive Compensation